These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25982493)

  • 1. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
    Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
    ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.
    Di Leva FS; Festa C; D'Amore C; De Marino S; Renga B; D'Auria MV; Novellino E; Limongelli V; Zampella A; Fiorucci S
    J Med Chem; 2013 Jun; 56(11):4701-17. PubMed ID: 23656455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
    Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
    J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
    Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
    Yu DD; Lin W; Forman BM; Chen T
    Bioorg Med Chem; 2014 Jun; 22(11):2919-38. PubMed ID: 24775917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
    Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
    Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists.
    Nian SY; Wang GP; Jiang ZL; Xiao Y; Huang MH; Zhou YH; Tan XD
    Mol Divers; 2019 Feb; 23(1):19-33. PubMed ID: 29974364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
    Schmidt J; Schierle S; Gellrich L; Kaiser A; Merk D
    Bioorg Med Chem; 2018 Aug; 26(14):4240-4253. PubMed ID: 30026040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
    Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
    Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
    Yu DD; Lin W; Chen T; Forman BM
    Bioorg Med Chem; 2013 Jul; 21(14):4266-78. PubMed ID: 23688559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
    Genin MJ; Bueno AB; Agejas Francisco J; Manninen PR; Bocchinfuso WP; Montrose-Rafizadeh C; Cannady EA; Jones TM; Stille JR; Raddad E; Reidy C; Cox A; Michael MD; Michael LF
    J Med Chem; 2015 Dec; 58(24):9768-72. PubMed ID: 26568144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists.
    Teno N; Iguchi Y; Yamashita Y; Mori N; Une M; Nishimaki-Mogami T; Gohda K
    Bioorg Med Chem; 2017 Mar; 25(6):1787-1794. PubMed ID: 28190654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
    Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
    Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
    Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.
    Li W; Fu J; Cheng F; Zheng M; Zhang J; Liu G; Tang Y
    J Chem Inf Model; 2012 Nov; 52(11):3043-52. PubMed ID: 23101941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.